Epicutis

The brand's creation stems from decades of Signum Biosciences' work as an ingredient supplier for the cosmetics industry, particularly in Japan. This experience led to a partnership between technology discovered by Dr. Jeffry Stock, a Professor of Molecular Biology at Princeton University, and the expertise of expert formulator Masanori Tamura. Tamura, who previously created Japan's top-selling skincare line, Hada Labo, was brought on as Chief Formulator to develop the Epicutis line. His background includes a master's degree in engineering from the University of Tokyo and over a decade at Rohto Pharmaceuticals.

Epicutis products are developed for and sold through skincare professionals, such as in spas and med-spas, and are not a direct-to-consumer brand. The business model leverages these professional channels for distribution, with a presence in 3,500 locations across 16 countries. The company has shown significant growth, with a reported 200% annual sales acceleration and a 65% reorder rate. Following a $3 million Series A, Epicutis secured $10 million in Series B funding to fuel global distribution, product innovation, and marketing.

The product philosophy emphasizes minimal ingredients with maximum efficacy. For example, their flagship Lipid Serum contains only eight ingredients. Key patented ingredients developed in-house include TSC, a small molecule that reduces inflammation, provides antioxidant properties, and protects collagen, and HYVIA, a patented chia seed oil extract that improves cellular hydration. The product line includes the Lipid Serum, HYVIA Crème, Oil Cleanser, and Lipid Recovery Masks, priced in the luxury segment from $75 to $250.